AAPG
Ascentage Pharma Group Internat
Price Chart
Latest Quote
$20.40
+0.29 (+1.44%)
Current Price
| Previous Close | $20.11 |
| Open | $20.14 |
| Day High | $20.40 |
| Day Low | $20.14 |
| Volume | 1,684 |
Stock Information
Note: Financial values converted from CNY to USD
| Shares Outstanding | 93.34M |
| Total Debt | $292.13M |
| Cash Equivalents | $364.81M |
| Revenue | $84.72M |
| Net Income | $-183.39M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.75B |
| EPS (TTM) | $-2.05 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.25B |
| Sales | $84.72M |
| Income | $-183.39M |
| Book/sh | $2.11 |
| Cash/sh | $26.49 |
| Employees | 767 |
Financial Ratios
| Quick Ratio | 1.69 |
| Current Ratio | 1.79 |
| Debt/Eq | 148.38 |
Returns & Margins
| ROA | -23.02% |
| ROE | -154.56% |
| Gross Margin | 91.48% |
| Operating Margin | -193.35% |
| Profit Margin | -216.47% |
Ownership
| Institutional Ownership | 0.06% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -15.75 |
| P/S | 3.05 |
| P/B | 8.88 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $47.56 |
Technical Indicators
| SMA20 | $18.39 |
| SMA50 | $18.89 |
| SMA200 | $25.88 |
| RSI | 61.71 |
| ATR | 0.8785 |
| Shares Float | 71.06M |
| Short Float | 0.21% |
| Short Ratio | 8.42 |
| Volatility | 0.66 |
| Rel Volume | 0.64 |
Performance History
| Week | -6.16% |
| Month | +10.17% |
| Quarter | -31.00% |
| 6 Months | -33.83% |
| YTD | -28.93% |
| Year | -51.48% |
| 10 Years | +7.83% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $18.74 | 12,100 |
| 2026-07-16 | $20.40 | 2,000 |
| 2026-07-15 | $20.18 | 15,400 |
| 2026-07-14 | $19.24 | 3,100 |
| 2026-07-13 | $19.60 | 3,400 |
| 2026-07-10 | $19.97 | 3,600 |
| 2026-07-09 | $18.90 | 9,000 |
| 2026-07-08 | $18.86 | 7,600 |
| 2026-07-07 | $18.68 | 7,800 |
| 2026-07-06 | $19.37 | 12,900 |
| 2026-07-02 | $18.50 | 13,500 |
| 2026-07-01 | $17.96 | 14,900 |
| 2026-06-30 | $17.56 | 700 |
| 2026-06-29 | $17.70 | 10,900 |
| 2026-06-26 | $16.77 | 195,400 |
| 2026-06-25 | $17.05 | 6,900 |
| 2026-06-24 | $17.08 | 7,100 |
| 2026-06-23 | $17.01 | 17,800 |
| 2026-06-22 | $17.13 | 23,100 |
| 2026-06-18 | $17.12 | 12,800 |
About Ascentage Pharma Group Internat
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
đ° Latest News
How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23%
Zacks âĸ 2026-07-09T13:55:02Z
Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development
Insider Monkey âĸ 2026-06-30T13:20:46Z
A Look At Ascentage Pharma Group Internationalâs Valuation After Recent Share Price Weakness
Simply Wall St. âĸ 2026-06-08T12:05:17Z
Ascentage Pharma (AAPG) Reports Phase 1b Olverembatinib Data
Insider Monkey âĸ 2026-06-05T21:03:38Z
Global Growth Companies Insiders Favor With Up To 40% Earnings Growth
Simply Wall St. âĸ 2026-05-25T09:35:57Z
Global Growth Companies With High Insider Ownership In April 2026
Simply Wall St. âĸ 2026-04-22T09:35:49Z
Global Growth Companies With High Insider Ownership
Simply Wall St. âĸ 2026-04-20T09:35:53Z
Global Insights Into 3 Growth Stocks With High Insider Ownership
Simply Wall St. âĸ 2026-04-17T09:36:19Z
Ascentage Pharma Builds Momentum With 2 'Potential Blockbuster' Drugs, Oppenheimer Says
MT Newswires âĸ 2026-03-27T15:26:50ZA Look At Ascentage Pharma Group Internationalâs Valuation After Recent Share Price Moves
Simply Wall St. âĸ 2026-03-09T05:05:52Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $7,224,068 | $4,293,433 | $4,508,658 | $3,247,273 |
| Cost Of Revenue | $7,224,068 | $4,293,433 | $4,508,658 | $3,247,273 |
| Total Revenue | $84,749,717 | $144,760,346 | $32,768,552 | $30,956,852 |
| Operating Revenue | $73,700,900 | $138,649,014 | $28,569,004 | $30,956,852 |
| Expenses | ||||
| Interest Expense | $7,981,637 | $9,514,636 | $14,179,620 | $7,791,949 |
| Total Expenses | $261,548,946 | $199,338,680 | $161,584,225 | $156,403,025 |
| Other Income Expense | $-9,803,375 | $160,902 | $505,144 | $840,825 |
| Other Non Operating Income Expenses | $-8,179,738 | $-655,566 | $-206,959 | $-451,707 |
| Net Non Operating Interest Income Expense | $4,141,387 | $-3,928,819 | $-9,395,510 | $-6,356,081 |
| Interest Expense Non Operating | $7,981,637 | $9,514,636 | $14,179,620 | $7,791,949 |
| Operating Expense | $254,324,878 | $195,045,247 | $157,075,567 | $153,155,753 |
| Other Operating Expenses | $-2,139,852 | $-1,339,327 | $-2,857,565 | $-4,959,479 |
| Selling And Marketing Expense | $52,203,180 | $28,932,584 | $28,842,390 | $23,237,973 |
| General And Administrative Expense | $36,355,196 | $27,622,781 | $26,729,847 | $25,182,676 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-183,453,496 | $-59,848,694 | $-136,639,507 | $-130,334,354 |
| Net Interest Income | $4,141,387 | $-3,928,819 | $-9,395,510 | $-6,356,081 |
| Interest Income | $12,123,024 | $5,585,817 | $4,784,111 | $1,435,868 |
| Normalized Income | $-182,201,005 | $-60,492,155 | $-137,188,534 | $-131,661,255 |
| Net Income From Continuing And Discontinued Operation | $-183,453,496 | $-59,848,694 | $-136,639,507 | $-130,334,354 |
| Net Income Common Stockholders | $-183,453,496 | $-59,848,694 | $-136,639,507 | $-130,334,354 |
| Net Income | $-183,453,496 | $-59,848,694 | $-136,639,507 | $-130,334,354 |
| Net Income Including Noncontrolling Interests | $-183,485,676 | $-59,885,155 | $-136,650,578 | $-130,334,354 |
| Net Income Continuous Operations | $-183,485,676 | $-59,885,155 | $-136,650,578 | $-130,334,354 |
| Pretax Income | $-182,461,216 | $-58,346,251 | $-137,706,038 | $-130,961,430 |
| Special Income Charges | $-2,657 | $-7,381 | $590 | $305,271 |
| Earnings From Equity Interest | $46,352 | $-41,480 | $158,836 | $-41,037 |
| Interest Income Non Operating | $12,123,024 | $5,585,817 | $4,784,111 | $1,435,868 |
| Operating Income | $-176,799,229 | $-54,578,334 | $-128,815,673 | $-125,446,173 |
| Gross Profit | $77,525,649 | $140,466,914 | $28,259,894 | $27,709,579 |
| Depreciation Amortization Depletion Income Statement | - | - | - | - |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Depreciation Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | - | $-0.79 | $-1.94 | $-1.98 |
| Basic EPS | - | $-0.79 | $-1.94 | $-1.98 |
| Other | ||||
| Tax Effect Of Unusual Items | $-417,497 | $214,487 | $4,241 | $6,668 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-160,043,697 | $-35,936,260 | $-110,322,544 | $-115,215,743 |
| Total Unusual Items | $-1,669,988 | $857,948 | $553,268 | $1,333,570 |
| Total Unusual Items Excluding Goodwill | $-1,669,988 | $857,948 | $553,268 | $1,333,570 |
| Reconciled Depreciation | $12,765,895 | $13,753,303 | $13,757,141 | $9,287,307 |
| EBITDA (Bullshit earnings) | $-161,713,685 | $-35,078,311 | $-109,769,277 | $-113,882,174 |
| EBIT | $-174,479,580 | $-48,831,614 | $-123,526,418 | $-123,169,480 |
| Diluted NI Availto Com Stockholders | $-183,453,496 | $-59,848,694 | $-136,639,507 | $-130,334,354 |
| Minority Interests | $32,180 | $36,461 | $11,071 | $0 |
| Tax Provision | $1,024,460 | $1,538,904 | $-1,055,460 | $-627,076 |
| Gain On Sale Of Ppe | $-2,657 | $-7,381 | $590 | $305,271 |
| Gain On Sale Of Security | $-1,667,331 | $865,329 | $552,677 | $1,028,298 |
| Research And Development | $167,906,354 | $139,829,209 | $104,360,895 | $109,694,583 |
| Selling General And Administration | $88,558,376 | $56,555,364 | $55,572,237 | $48,420,649 |
| Other Gand A | $36,355,196 | $27,622,781 | $26,729,847 | $25,182,676 |
| Diluted Average Shares | - | $11,147,355 | $10,418,024 | $9,731,221 |
| Basic Average Shares | - | $11,147,355 | $10,418,024 | $9,731,221 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
| Other Special Charges | - | - | $-590 | $-305,271 |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-07-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $182,134,245 | $24,135,631 | $-7,339,947 | $44,234,829 |
| Total Assets | $585,090,276 | $386,432,552 | $369,099,838 | $417,793,874 |
| Total Non Current Assets | $150,481,085 | $168,821,578 | $170,676,677 | $176,220,867 |
| Non Current Prepaid Assets | $101,856 | $360,037 | $442,850 | $959,509 |
| Non Current Deferred Assets | $9,123,895 | $11,036,565 | $8,833,680 | $8,014,703 |
| Non Current Deferred Taxes Assets | $4,717,388 | $6,529,974 | $8,833,680 | $8,014,703 |
| Investmentin Financial Assets | $590,467 | $168,431 | $288,000 | $385,132 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $590,467 | $168,431 | $288,000 | $385,132 |
| Goodwill And Other Intangible Assets | $13,378,504 | $14,863,824 | $16,258,507 | $16,089,928 |
| Other Intangible Assets | $9,733,257 | $11,218,576 | $12,613,259 | $12,444,681 |
| Current Assets | $434,609,191 | $217,610,974 | $198,423,161 | $241,573,007 |
| Restricted Cash | $839,201 | $3,636,243 | $3,622,072 | $2,450,585 |
| Prepaid Assets | $21,305,375 | $15,836,323 | $10,427,351 | $10,821,930 |
| Inventory | $4,224,496 | $973,828 | $2,386,520 | $1,394,683 |
| Receivables | $44,453,450 | $14,624,980 | $24,141,240 | $9,076,805 |
| Other Receivables | $214,782 | $905,924 | $979,732 | $95,803 |
| Taxes Receivable | $6,900,787 | $1,445,758 | $1,625,260 | $957,147 |
| Accounts Receivable | $37,337,880 | $12,273,298 | $21,536,248 | $8,023,855 |
| Cash Cash Equivalents And Short Term Investments | $363,786,669 | $182,539,601 | $157,845,979 | $217,829,004 |
| Cash And Cash Equivalents | $363,786,669 | $182,539,601 | $157,845,979 | $217,829,004 |
| Cash Equivalents | $187,268,946 | $50,703,099 | $4,612,728 | $19,190,175 |
| Cash Financial | $176,517,724 | $131,836,502 | $153,233,251 | $198,638,829 |
| Non Current Accounts Receivable | - | $3,843,054 | $1,040,993 | - |
| Other Non Current Assets | - | - | - | $1,151,853 |
| Debt | ||||
| Total Debt | $292,239,645 | $246,298,071 | $265,059,862 | $264,636,498 |
| Long Term Debt And Capital Lease Obligation | $111,780,997 | $131,295,486 | $174,068,319 | $188,114,494 |
| Long Term Debt | $109,579,589 | $128,226,092 | $172,160,521 | $186,764,687 |
| Current Debt And Capital Lease Obligation | $180,458,648 | $115,002,585 | $90,991,543 | $76,522,003 |
| Current Debt | $179,383,555 | $113,609,231 | $89,551,246 | $75,329,555 |
| Other Current Borrowings | $179,383,555 | $113,609,231 | $89,551,246 | $75,329,555 |
| Net Debt | - | $59,295,721 | $103,865,788 | $44,265,238 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $388,138,263 | $345,961,654 | $358,673,374 | $357,469,116 |
| Total Non Current Liabilities Net Minority Interest | $145,549,062 | $173,750,353 | $220,773,810 | $227,396,339 |
| Other Non Current Liabilities | $1,775,977 | $926,147 | - | - |
| Non Current Deferred Liabilities | $31,992,088 | $41,528,719 | $44,004,252 | $34,066,398 |
| Non Current Deferred Taxes Liabilities | $0 | $792,407 | $1,557,209 | $1,793,691 |
| Current Liabilities | $242,589,201 | $172,211,301 | $137,899,564 | $130,072,777 |
| Other Current Liabilities | $290,510 | - | - | $416,574 |
| Current Deferred Liabilities | $8,869,551 | $7,983,851 | $5,669,959 | $3,595,058 |
| Payables And Accrued Expenses | $52,970,492 | $49,224,865 | $41,238,062 | $49,539,141 |
| Payables | $34,628,523 | $37,141,550 | $34,140,354 | $44,241,915 |
| Other Payable | $16,849,564 | $22,144,724 | $22,207,904 | $29,076,067 |
| Total Tax Payable | $2,022,349 | $1,421,106 | $1,238,357 | $1,059,741 |
| Accounts Payable | $15,756,610 | $13,575,720 | $10,694,094 | $14,106,107 |
| Tradeand Other Payables Non Current | - | $0 | $2,701,239 | $5,215,447 |
| Interest Payable | - | - | $154,407 | $56,537 |
| Equity | ||||
| Common Stock Equity | $195,512,749 | $38,999,454 | $8,918,560 | $60,324,758 |
| Total Equity Gross Minority Interest | $196,952,013 | $40,470,898 | $10,426,465 | $60,324,758 |
| Stockholders Equity | $195,512,749 | $38,999,454 | $8,918,560 | $60,324,758 |
| Gains Losses Not Affecting Retained Earnings | $-85,080,674 | $-75,371,036 | $-74,466,883 | $-76,541,341 |
| Other Equity Adjustments | $-58,644,584 | $-56,760,847 | $-54,830,906 | $-53,029,096 |
| Retained Earnings | $-1,035,283,955 | $-851,830,459 | $-791,981,766 | $-655,342,259 |
| Long Term Equity Investment | $4,875,781 | $4,829,577 | $2,509,189 | $2,350,354 |
| Other | ||||
| Ordinary Shares Number | $55,108,527 | $46,532,483 | $42,837,867 | $39,145,883 |
| Share Issued | $55,108,527 | $46,532,483 | $42,837,867 | $39,145,883 |
| Tangible Book Value | $182,134,245 | $24,135,631 | $-7,339,947 | $44,234,829 |
| Invested Capital | $484,475,894 | $280,834,777 | $270,630,327 | $322,419,000 |
| Working Capital | $192,019,990 | $45,399,673 | $60,523,597 | $111,500,230 |
| Capital Lease Obligations | $3,276,501 | $4,462,749 | $3,348,095 | $2,542,255 |
| Total Capitalization | $305,092,339 | $167,225,546 | $181,079,081 | $247,089,444 |
| Minority Interest | $1,439,263 | $1,471,444 | $1,507,905 | $0 |
| Foreign Currency Translation Adjustments | $-26,436,090 | $-18,610,189 | $-19,635,977 | $-23,512,245 |
| Treasury Stock | $437,093 | $1,181 | $3,151,765 | $3,919,519 |
| Additional Paid In Capital | $1,316,276,682 | $966,170,540 | $878,489,893 | $796,101,306 |
| Capital Stock | $37,790 | $31,590 | $29,080 | $26,571 |
| Common Stock | $37,790 | $31,590 | $29,080 | $26,571 |
| Non Current Deferred Revenue | $31,992,088 | $40,736,313 | $42,447,043 | $32,272,708 |
| Long Term Capital Lease Obligation | $2,201,408 | $3,069,395 | $1,907,799 | $1,349,807 |
| Current Deferred Revenue | $8,869,551 | $7,983,851 | $5,669,959 | $3,595,058 |
| Current Capital Lease Obligation | $1,075,093 | $1,393,354 | $1,440,296 | $1,192,448 |
| Current Accrued Expenses | $18,341,969 | $12,083,315 | $7,097,708 | $5,297,226 |
| Investments And Advances | $5,466,248 | $4,998,007 | $2,797,189 | $2,735,486 |
| Investmentsin Joint Venturesat Cost | $4,875,781 | $4,829,577 | $2,509,189 | $2,350,354 |
| Goodwill | $3,645,248 | $3,645,248 | $3,645,248 | $3,645,248 |
| Net PPE | $122,410,583 | $133,720,091 | $141,303,458 | $95,954,565 |
| Accumulated Depreciation | $-42,370,282 | $-32,688,692 | $-22,265,179 | $-10,418,051 |
| Gross PPE | $164,780,865 | $166,408,783 | $163,568,637 | $106,372,616 |
| Leases | $8,965,354 | $6,530,417 | $4,313,066 | $1,142,701 |
| Construction In Progress | $338,633 | $1,121,001 | $1,891,708 | $6,021,877 |
| Machinery Furniture Equipment | $27,542,625 | $27,064,494 | $26,551,083 | $22,911,888 |
| Buildings And Improvements | $124,193,941 | $127,785,751 | $126,738,853 | $72,055,416 |
| Land And Improvements | $3,740,313 | $3,907,120 | $4,073,927 | $4,240,733 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-617,038 | $0 | - | - |
| Finished Goods | $1,096,349 | $569,948 | $1,635,298 | $650,990 |
| Work In Process | $3,745,184 | $403,879 | $751,222 | $743,693 |
| Investment Properties | - | - | $0 | $52,466,676 |
| Other Properties | - | - | - | $95,762,220 |
| Line Of Credit | - | - | - | - |
Fetched: 2026-07-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-177,390,877 | $-20,023,619 | $-115,572,238 | $-131,508,497 |
| Operating Activities | ||||
| Operating Cash Flow | $-173,320,936 | $-16,438,156 | $-107,181,112 | $-96,528,794 |
| Cash Flow From Continuing Operating Activities | $-173,320,936 | $-16,438,156 | $-107,181,112 | $-96,528,794 |
| Operating Gains Losses | $1,456,239 | $-939,285 | $-815,287 | $-2,734,009 |
| Investing Activities | ||||
| Capital Expenditure | $-4,069,941 | $-3,585,463 | $-8,391,125 | $-34,979,703 |
| Investing Cash Flow | $-147,624,406 | $-53,442,423 | $3,236,054 | $-56,775,166 |
| Cash Flow From Continuing Investing Activities | $-147,624,406 | $-53,442,423 | $3,236,054 | $-56,775,166 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,333,865 | $0 | $-874,334 | $-3,952,586 |
| Issuance Of Capital Stock | $340,242,539 | $78,818,477 | $69,391,820 | $0 |
| Financing Cash Flow | $374,961,256 | $46,464,875 | $54,433,817 | $91,414,317 |
| Cash Flow From Continuing Financing Activities | $374,961,256 | $46,464,875 | $54,433,817 | $91,414,317 |
| Net Other Financing Charges | $-1,731,249 | $-1,960,793 | $1,518,976 | - |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $338,908,674 | $78,818,477 | $68,517,486 | $-3,952,586 |
| Common Stock Issuance | $340,242,539 | $78,818,477 | $69,391,820 | $0 |
| Other | ||||
| Repayment Of Debt | $-137,830,774 | $-100,565,816 | $-142,724,269 | $-10,000,000 |
| Issuance Of Debt | $183,187,933 | $79,111,201 | $140,752,552 | $112,722,645 |
| End Cash Position | $176,517,724 | $131,836,502 | $153,233,251 | $198,638,829 |
| Beginning Cash Position | $131,836,502 | $153,233,251 | $198,638,829 | $251,964,930 |
| Effect Of Exchange Rate Changes | $-9,334,692 | $2,018,954 | $4,105,664 | $8,563,542 |
| Changes In Cash | $54,015,914 | $-23,415,704 | $-49,511,242 | $-61,889,643 |
| Interest Paid Cff | $-7,573,919 | $-8,939,079 | $-13,632,110 | $-7,358,546 |
| Proceeds From Stock Option Exercised | $590 | $886 | $1,181 | $2,805 |
| Common Stock Payments | $-1,333,865 | $0 | $-874,334 | $-3,952,586 |
| Net Issuance Payments Of Debt | $45,357,159 | $-21,454,616 | $-1,971,717 | $102,722,644 |
| Net Long Term Debt Issuance | $45,357,159 | $-21,454,616 | $-1,971,717 | $102,722,644 |
| Long Term Debt Payments | $-137,830,774 | $-100,565,816 | $-142,724,269 | $-10,000,000 |
| Long Term Debt Issuance | $183,187,933 | $79,111,201 | $140,752,552 | $112,722,645 |
| Net Investment Purchase And Sale | $-137,156,461 | $-46,090,372 | $14,577,447 | $-19,190,175 |
| Purchase Of Investment | $-137,156,461 | $-46,090,372 | $0 | $-19,190,175 |
| Net Business Purchase And Sale | $-6,398,004 | $-3,766,588 | $-2,952,335 | $-2,952,335 |
| Purchase Of Business | $-6,398,004 | $-3,766,588 | $-2,952,335 | $-2,952,335 |
| Net Intangibles Purchase And Sale | $0 | $0 | $-1,584,813 | $-4,970,993 |
| Purchase Of Intangibles | $0 | $0 | $-1,584,813 | $-4,970,993 |
| Net PPE Purchase And Sale | $-4,069,941 | $-3,585,463 | $-6,804,246 | $-29,661,663 |
| Sale Of PPE | $0 | $0 | $2,067 | $347,047 |
| Purchase Of PPE | $-4,069,941 | $-3,585,463 | $-6,806,312 | $-30,008,710 |
| Taxes Refund Paid | $-4,281 | $0 | $0 | $0 |
| Change In Working Capital | $-21,183,444 | $16,380,438 | $-1,350,103 | $15,413,106 |
| Change In Other Working Capital | $-2,588,755 | $588,991 | $11,077,750 | $-638,295 |
| Change In Other Current Assets | $4,101,383 | $-7,225,839 | $-524,335 | $4,336,980 |
| Change In Payables And Accrued Expense | $18,981,002 | $14,470,425 | $3,758,174 | $12,126,124 |
| Change In Payable | $18,981,002 | $14,470,425 | $3,758,174 | $12,126,124 |
| Change In Account Payable | $2,180,890 | $2,881,626 | $-3,412,013 | $3,645,838 |
| Change In Prepaid Assets | $-12,744,786 | $-2,128,781 | $-1,157,463 | $460,121 |
| Change In Inventory | $-3,867,706 | $1,412,692 | $-991,837 | $-814,549 |
| Change In Receivables | $-25,064,583 | $9,262,950 | $-13,512,393 | $-57,275 |
| Changes In Account Receivables | $-25,064,583 | $9,262,950 | $-13,512,393 | $-57,275 |
| Other Non Cash Items | $12,240,084 | $9,502,089 | $14,179,620 | $7,761,688 |
| Stock Based Compensation | $3,081,352 | $3,088,732 | $4,650,370 | $3,263,068 |
| Unrealized Gain Loss On Investment Securities | $167,397 | $122,817 | $103,184 | $1,441,477 |
| Asset Impairment Charge | $617,038 | $0 | $0 | - |
| Depreciation Amortization Depletion | $12,765,895 | $13,753,303 | $13,757,141 | $9,287,307 |
| Depreciation And Amortization | $12,765,895 | $13,753,303 | $13,757,141 | $9,287,307 |
| Amortization Cash Flow | $1,485,320 | $1,601,789 | $1,535,066 | $1,443,987 |
| Amortization Of Intangibles | $1,485,320 | $1,601,789 | $1,535,066 | $1,443,987 |
| Depreciation | $11,280,575 | $12,151,514 | $12,222,075 | $7,843,320 |
| Earnings Losses From Equity Investments | $-46,352 | $41,480 | $-158,836 | $41,037 |
| Net Foreign Currency Exchange Gain Loss | $1,499,934 | $-988,146 | $-239,287 | $399,008 |
| Gain Loss On Sale Of PPE | $2,657 | $7,381 | $-590 | $-305,271 |
| Net Income From Continuing Operations | $-182,461,216 | $-58,346,251 | $-137,706,038 | $-130,961,430 |
| Sale Of Investment | - | - | $14,577,447 | $0 |
| Gain Loss On Investment Securities | - | - | $-416,574 | $-2,868,784 |
| Change In Other Current Liabilities | - | - | - | $0 |
Fetched: 2026-07-17